Suppr超能文献

同种异体造血干细胞移植相关并发症早期的止血参数改变。

Alterations of hemostatic parameters in the early development of allogeneic hematopoietic stem cell transplantation-related complications.

机构信息

Department of Hematology, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, No.188 Shi Zi Street, Suzhou, People's Republic of China.

出版信息

Ann Hematol. 2011 Oct;90(10):1201-8. doi: 10.1007/s00277-011-1273-5. Epub 2011 Jun 15.

Abstract

Thrombotic events are common and potentially fatal complications in patients receiving hematopoietic stem cell transplantation (HSCT). Early diagnosis is crucial but remains controversial. In this study, we investigated the early alterations of hemostatic parameters in allogeneic HSCT recipients and determined their potential diagnostic values in transplantation-related thrombotic complications and other post-HSCT events. Results from 107 patients with allogeneic HSCT showed higher levels of plasma plasminogen activator inhibitor-1 (PAI-1), fibrinogen, and tissue-plasminogen activator (t-PA) and a lower level of plasma protein C after transplantation. No change was found for prothrombin time, antithrombin III, D: -dimer, and activated partial thromboplastin time following HSCT. Transplantation-related complications (TRCs) in HSCT patients were defined as thrombotic (n=8), acute graft-versus-host disease (aGVHD, n=45), and infectious (n=38). All patients with TRCs, especially the patients with thrombotic complications, presented significant increases in the mean and maximum levels of PAI-1 during the observation period. Similarly, a high maximum t-PA level was found in the thrombotic group. In contrast, apparent lower levels of mean and minimum protein C were observed in the TRC patients, especially in the aGVHD group. Therefore, the hemostatic imbalance in the early phase of HSCT, reflecting prothrombotic state and endothelial injury due to the conditioning therapy or TRCs, might be useful in the differential diagnosis of the thrombotic complication from other TRCs.

摘要

血栓事件是接受造血干细胞移植(HSCT)的患者常见且潜在致命的并发症。早期诊断至关重要,但仍存在争议。在这项研究中,我们研究了异基因 HSCT 受者止血参数的早期变化,并确定了它们在移植相关血栓并发症和其他 HSCT 后事件中的潜在诊断价值。107 例异基因 HSCT 患者的结果显示,移植后血浆纤溶酶原激活物抑制剂-1(PAI-1)、纤维蛋白原和组织型纤溶酶原激活物(t-PA)水平升高,血浆蛋白 C 水平降低。HSCT 后凝血酶原时间、抗凝血酶 III、D-二聚体和活化部分凝血活酶时间无变化。HSCT 患者的移植相关并发症(TRC)定义为血栓形成(n=8)、急性移植物抗宿主病(aGVHD,n=45)和感染(n=38)。所有 TRC 患者,尤其是血栓形成并发症患者,在观察期间 PAI-1 的平均和最大水平均显著升高。同样,血栓形成组中也发现 t-PA 水平较高。相反,TRC 患者,尤其是 aGVHD 组,蛋白 C 的平均和最小水平明显较低。因此,HSCT 早期的止血失衡反映了由于调理治疗或 TRC 导致的血栓前状态和内皮损伤,可能有助于将血栓并发症与其他 TRC 进行鉴别诊断。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e1e8/3168446/8e66039d15b3/277_2011_1273_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验